From Financial Modeling Prep: 2025-04-03 10:00:00

Lexaria Bioscience Corp. (NASDAQ:LEXX) is a biotech company known for its innovative drug delivery technology, DehydraTECH. They are set to release quarterly earnings with an estimated EPS of -$0.16 and projected revenue of $137,000 on April 8, 2025.

The company is conducting a human study on DehydraTECH, showing promise in weight reduction and blood sugar level decrease. Results from a rodent study indicated a 5.88% weight reduction and an 11.54% decrease in blood sugar levels.

Despite a negative P/E ratio of -3.60, LEXX’s financial metrics highlight a strong current ratio of 29.64 and a low debt-to-equity ratio of 0.013. Investors are optimistic about the potential growth driven by the company’s innovative research and drug delivery technology.



Read more at Financial Modeling Prep:: Lexaria Bioscience Corp. (NASDAQ:LEXX) Earnings Pr…